Shopping Cart 0
Cart Subtotal
AED 0

Celldex Therapeutics Inc (CLDX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 2753

Details

Summary

Celldex Therapeutics Inc (Celldex) is a bio-pharmaceutical company that discovers, develops and commercializes targeted immunotherapy technologies and cancer-targeting biologicsfor the treatment of various types of cancers. The company's developmental pipeline comprises therapeutic antibodies, antibody drug conjugates (ADCs), immune system modulators, vaccines and other protein-based therapeutics. Its key products in development include glembatumumabvedotin; Varlilumab; CDX-1401; CDX-3379; CDX-0158; CDX-301; and CDX-014. Celldex's products find application in the treatment of various indications such as brain cancer, triple negative breast cancer, lymphoma/leukemia, melanoma, and renal cell carcinoma. It operates a manufacturing facility in Fall River, Massachusetts; and research laboratories in Massachusetts, New Jersey and Connecticut. Celldex is headquartered in Hampton, New Jersey, the US.

Celldex Therapeutics Inc (CLDX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Celldex Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Celldex Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Celldex Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Celldex Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Celldex Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 11

Celldex Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Celldex Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 14

Venture Financing 14

Kolltan Pharma Raises USD 60 Million In Series D Financing 14

Kolltan Pharma Raises USD 25 Million In Series C Financing 16

Partnerships 17

Celldex Therapeutics Enters into Agreement with Roche 17

Licensing Agreements 18

Shanghai Henlius Biotech Enters into Licensing Agreement with Kolltan Pharma for KTN0216 18

Kolltan Pharma Enters into Licensing Agreement with Spirogen 19

Kolltan Pharma Enters Into Licensing Agreement With University of Toronto For Anti-KIT Antibodies And Related IP 20

Kolltan Pharma Enters Into Licensing Agreement With MedImmune 21

Kolltan Pharma Enters Into Licensing And Research Agreement With Children's Hospital of Philadelphia For Pediatric Neuroblastoma Therapies 22

Equity Offering 23

Celldex Therapeutics Files Registration Statement for Public Offering of Shares 23

Celldex Therapeutics to Raise up to USD48.8 Million in Final Tranche of Public Offering of Shares 24

Celldex Therapeutics Raises USD200 Million in Public Offering of Shares 25

Kolltan Pharma Withdraws IPO 27

Celldex Therapeutics Completes Public Offering Of Shares For USD 191.4 Million 28

Celldex Therapeutics Completes Public Offering Of Shares For USD 104 Million 30

Celldex Therapeutics Completes Second Tranche Of Private Placement Of Shares For USD 7.3 Million 32

Celldex Therapeutics Completes Third Tranche Of Private Placement Of Shares For USD 21 Million 33

Celldex Therapeutics Completes Underwriters' Exercise Of Over-Allotment Option For USD 46 Million 35

Acquisition 37

Celldex Therapeutics Acquires Kolltan Pharma 37

Kolltan Pharma Acquires Xetrios Therapeutics 38

Celldex Therapeutics Inc-Key Competitors 39

Celldex Therapeutics Inc-Key Employees 40

Celldex Therapeutics Inc-Locations And Subsidiaries 41

Head Office 41

Other Locations & Subsidiaries 41

Recent Developments 43

Financial Announcements 43

Nov 07, 2018: Celldex provides corporate update and reports third quarter 2018 results 43

Aug 08, 2018: Celldex provides corporate update and reports second quarter 2018 results 45

May 10, 2018: Celldex Provides Corporate Update and Reports First Quarter 2018 Results 47

Mar 07, 2018: Celldex Provides Corporate Update and Reports Full Year 2017 Results 50

Nov 07, 2017: Celldex Reports Third Quarter 2017 Results 52

Aug 08, 2017: Celldex Reports Second Quarter 2017 Results 56

May 09, 2017: Celldex Reports First Quarter 2017 Results 58

Mar 14, 2017: Celldex Provides Corporate Update and Reports Full Year 2016 Results 60

Corporate Communications 62

Oct 03, 2017: Celldex Therapeutics Appoints Margo Heath-Chiozzi, M.D., as Senior Vice President, Regulatory Affairs 62

Sep 12, 2017: Celldex Announces Departure of Chief Medical Officer 63

Jun 16, 2017: Celldex Therapeutics Announces Additions to the Board of Directors and Senior Management Team 64

Mar 01, 2017: Celldex Therapeutics Announces Appointment to Board of Directors 65

Clinical Trials 66

Apr 20, 2018: Celldex Therapeutics presents data on CDX-1140 at AACR Annual Meeting 2018 66

Nov 30, 2017: Celldex Therapeutics Initiates Phase 1 Study of New Product Candidate CDX-1140 in Solid Tumors 67

May 17, 2017: Celldex Therapeutics to Present Clinical Results from Phase 2 Study of Glembatumumab Vedotin at 2017 ASCO Annual Meeting 68

Appendix 69

Methodology 69

About GlobalData 69

Contact Us 69

Disclaimer 69


List Of Figure

List of Figures

Celldex Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Celldex Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Celldex Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Celldex Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Celldex Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Celldex Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Celldex Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Celldex Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Celldex Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 11


List Of Table

List of Tables

Celldex Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Celldex Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Celldex Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Celldex Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Celldex Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Celldex Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 11

Celldex Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Kolltan Pharma Raises USD 60 Million In Series D Financing 14

Kolltan Pharma Raises USD 25 Million In Series C Financing 16

Celldex Therapeutics Enters into Agreement with Roche 17

Shanghai Henlius Biotech Enters into Licensing Agreement with Kolltan Pharma for KTN0216 18

Kolltan Pharma Enters into Licensing Agreement with Spirogen 19

Kolltan Pharma Enters Into Licensing Agreement With University of Toronto For Anti-KIT Antibodies And Related IP 20

Kolltan Pharma Enters Into Licensing Agreement With MedImmune 21

Kolltan Pharma Enters Into Licensing And Research Agreement With Children's Hospital of Philadelphia For Pediatric Neuroblastoma Therapies 22

Celldex Therapeutics Files Registration Statement for Public Offering of Shares 23

Celldex Therapeutics to Raise up to USD48.8 Million in Final Tranche of Public Offering of Shares 24

Celldex Therapeutics Raises USD200 Million in Public Offering of Shares 25

Kolltan Pharma Withdraws IPO 27

Celldex Therapeutics Completes Public Offering Of Shares For USD 191.4 Million 28

Celldex Therapeutics Completes Public Offering Of Shares For USD 104 Million 30

Celldex Therapeutics Completes Second Tranche Of Private Placement Of Shares For USD 7.3 Million 32

Celldex Therapeutics Completes Third Tranche Of Private Placement Of Shares For USD 21 Million 33

Celldex Therapeutics Completes Underwriters' Exercise Of Over-Allotment Option For USD 46 Million 35

Celldex Therapeutics Acquires Kolltan Pharma 37

Kolltan Pharma Acquires Xetrios Therapeutics 38

Celldex Therapeutics Inc, Key Competitors 39

Celldex Therapeutics Inc, Key Employees 40

Celldex Therapeutics Inc, Other Locations 41

Celldex Therapeutics Inc, Subsidiaries 41

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Celldex Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Celldex Therapeutics Inc (Celldex) is a bio-pharmaceutical company that discovers, develops and commercializes targeted immunotherapy technologies and cancer-targeting biologicsfor the treatment of various types of cancers. The company's developmental pipeline comprises therapeutic antibodies, antibody drug conjugates (ADCs), immune system modulators, vaccines and other protein-based therapeutics. Its key products in development include glembatumumabvedotin; Varlilumab; CDX-1401; CDX-3379; CDX-0158; CDX-301; and CDX-014. Celldex's products find application in the treatment of various indications such as brain cancer, triple negative breast cancer, lymphoma/leukemia, melanoma, and renal cell carcinoma. It operates a manufacturing facility in Fall River, Massachusetts; and research laboratories in Massachusetts, New Jersey and Connecticut. Celldex is headquartered in Hampton, New Jersey, the US.

Celldex Therapeutics Inc (CLDX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Celldex Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Celldex Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Celldex Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Celldex Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Celldex Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 11

Celldex Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Celldex Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 14

Venture Financing 14

Kolltan Pharma Raises USD 60 Million In Series D Financing 14

Kolltan Pharma Raises USD 25 Million In Series C Financing 16

Partnerships 17

Celldex Therapeutics Enters into Agreement with Roche 17

Licensing Agreements 18

Shanghai Henlius Biotech Enters into Licensing Agreement with Kolltan Pharma for KTN0216 18

Kolltan Pharma Enters into Licensing Agreement with Spirogen 19

Kolltan Pharma Enters Into Licensing Agreement With University of Toronto For Anti-KIT Antibodies And Related IP 20

Kolltan Pharma Enters Into Licensing Agreement With MedImmune 21

Kolltan Pharma Enters Into Licensing And Research Agreement With Children's Hospital of Philadelphia For Pediatric Neuroblastoma Therapies 22

Equity Offering 23

Celldex Therapeutics Files Registration Statement for Public Offering of Shares 23

Celldex Therapeutics to Raise up to USD48.8 Million in Final Tranche of Public Offering of Shares 24

Celldex Therapeutics Raises USD200 Million in Public Offering of Shares 25

Kolltan Pharma Withdraws IPO 27

Celldex Therapeutics Completes Public Offering Of Shares For USD 191.4 Million 28

Celldex Therapeutics Completes Public Offering Of Shares For USD 104 Million 30

Celldex Therapeutics Completes Second Tranche Of Private Placement Of Shares For USD 7.3 Million 32

Celldex Therapeutics Completes Third Tranche Of Private Placement Of Shares For USD 21 Million 33

Celldex Therapeutics Completes Underwriters' Exercise Of Over-Allotment Option For USD 46 Million 35

Acquisition 37

Celldex Therapeutics Acquires Kolltan Pharma 37

Kolltan Pharma Acquires Xetrios Therapeutics 38

Celldex Therapeutics Inc-Key Competitors 39

Celldex Therapeutics Inc-Key Employees 40

Celldex Therapeutics Inc-Locations And Subsidiaries 41

Head Office 41

Other Locations & Subsidiaries 41

Recent Developments 43

Financial Announcements 43

Nov 07, 2018: Celldex provides corporate update and reports third quarter 2018 results 43

Aug 08, 2018: Celldex provides corporate update and reports second quarter 2018 results 45

May 10, 2018: Celldex Provides Corporate Update and Reports First Quarter 2018 Results 47

Mar 07, 2018: Celldex Provides Corporate Update and Reports Full Year 2017 Results 50

Nov 07, 2017: Celldex Reports Third Quarter 2017 Results 52

Aug 08, 2017: Celldex Reports Second Quarter 2017 Results 56

May 09, 2017: Celldex Reports First Quarter 2017 Results 58

Mar 14, 2017: Celldex Provides Corporate Update and Reports Full Year 2016 Results 60

Corporate Communications 62

Oct 03, 2017: Celldex Therapeutics Appoints Margo Heath-Chiozzi, M.D., as Senior Vice President, Regulatory Affairs 62

Sep 12, 2017: Celldex Announces Departure of Chief Medical Officer 63

Jun 16, 2017: Celldex Therapeutics Announces Additions to the Board of Directors and Senior Management Team 64

Mar 01, 2017: Celldex Therapeutics Announces Appointment to Board of Directors 65

Clinical Trials 66

Apr 20, 2018: Celldex Therapeutics presents data on CDX-1140 at AACR Annual Meeting 2018 66

Nov 30, 2017: Celldex Therapeutics Initiates Phase 1 Study of New Product Candidate CDX-1140 in Solid Tumors 67

May 17, 2017: Celldex Therapeutics to Present Clinical Results from Phase 2 Study of Glembatumumab Vedotin at 2017 ASCO Annual Meeting 68

Appendix 69

Methodology 69

About GlobalData 69

Contact Us 69

Disclaimer 69


List Of Figure

List of Figures

Celldex Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Celldex Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Celldex Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Celldex Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Celldex Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Celldex Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Celldex Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Celldex Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Celldex Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 11


List Of Table

List of Tables

Celldex Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Celldex Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Celldex Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Celldex Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Celldex Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Celldex Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 11

Celldex Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Kolltan Pharma Raises USD 60 Million In Series D Financing 14

Kolltan Pharma Raises USD 25 Million In Series C Financing 16

Celldex Therapeutics Enters into Agreement with Roche 17

Shanghai Henlius Biotech Enters into Licensing Agreement with Kolltan Pharma for KTN0216 18

Kolltan Pharma Enters into Licensing Agreement with Spirogen 19

Kolltan Pharma Enters Into Licensing Agreement With University of Toronto For Anti-KIT Antibodies And Related IP 20

Kolltan Pharma Enters Into Licensing Agreement With MedImmune 21

Kolltan Pharma Enters Into Licensing And Research Agreement With Children's Hospital of Philadelphia For Pediatric Neuroblastoma Therapies 22

Celldex Therapeutics Files Registration Statement for Public Offering of Shares 23

Celldex Therapeutics to Raise up to USD48.8 Million in Final Tranche of Public Offering of Shares 24

Celldex Therapeutics Raises USD200 Million in Public Offering of Shares 25

Kolltan Pharma Withdraws IPO 27

Celldex Therapeutics Completes Public Offering Of Shares For USD 191.4 Million 28

Celldex Therapeutics Completes Public Offering Of Shares For USD 104 Million 30

Celldex Therapeutics Completes Second Tranche Of Private Placement Of Shares For USD 7.3 Million 32

Celldex Therapeutics Completes Third Tranche Of Private Placement Of Shares For USD 21 Million 33

Celldex Therapeutics Completes Underwriters' Exercise Of Over-Allotment Option For USD 46 Million 35

Celldex Therapeutics Acquires Kolltan Pharma 37

Kolltan Pharma Acquires Xetrios Therapeutics 38

Celldex Therapeutics Inc, Key Competitors 39

Celldex Therapeutics Inc, Key Employees 40

Celldex Therapeutics Inc, Other Locations 41

Celldex Therapeutics Inc, Subsidiaries 41

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Celldex Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.